摘要
为了观察改良EOF方案治疗晚期胃癌的疗效、不良反应及生存情况,采用EOF方案治疗晚期胃癌患者32例,表柔比星60mg/m2,d1,奥沙利铂130mg/m2,d1,5-FU3000mg/m2持续静脉滴入120h,每3周重复化疗,观察有效率、生存情况及不良反应。改良EOF方案治疗晚期胃癌有效率46.9%,中位生存时间10.1个月(95%CI:7.9～12.3个月),1年生存率40.6%。中位无进展生存时间6.9个月(95%CI:5.7～8.1个月)。不良反应主要为中性粒细胞减少、贫血、血小板减少、胃肠道反应、脱发和外周神经毒性等,多为Ⅰ～Ⅱ度。初步研究结果提示,改良EOF方案治疗晚期胃癌有效率与传统EOF方案相似,毒副反应可以耐受,治疗方便,临床可进一步扩大病例研究。
This study was to observe the effects ,adverse reactions and survival status of the regimen of modified EOF in the treatment of advanced gastric cancer（AGC）. Thirty-two patients with AGC were treated by EOF regimen from August. EOF regimen： epirubicin 60 mg/m^2, iv drop on d1 , oxaliplatin 130 mg/m^2 iv drop on d1 , 5-FU 3 000 mg/m^2 , 120 hours iv drop, and repeated every 3 weeks. The response rate, survival status and adverse reac tions were observed. The response rate was 46.9%. The median survival time and 1-year survival rate were 10.1 months （95% CI： 7.9 - 12.3 months） and 40.6%. The median progression-free survival time was 6.9 months （95% CI： 5.7-8.1 months）. The main toxicities were neutropenia, anemia, thrombocytopenia, adverse reaction of gastrointestinal tract, alopecie and neuro sensory toxicity, most of which were grade Ⅰ or Ⅱ. In conclusion, the response rate of the regimen of modified EOF in the treatment of AGC is similar to that of the orthodox EOF regimen. The toxicity is mild and toleratble.
出处
《中华肿瘤防治杂志》
CAS
2009年第7期550-552,共3页
Chinese Journal of Cancer Prevention and Treatment
关键词
胃肿瘤/药物疗法
表柔比星
氟尿嘧啶
奥沙利铂
药物疗法
联合
stomach neoplasms/drug therapy
epirubicin
5 fluorouracil
oxaliplatin
drug therapy, combination
